Literature DB >> 36100855

Novel frameshift mutation in LIS1 gene is a probable cause of lissencephaly: a case report.

Camila Simoes1,2, Martín Graña1, Soledad Rodriguez3, Federico Baltar Yanes4, Alejandra Tapié3, Nicolás Dell'Oca3, Hugo Naya1,5, Víctor Raggio3, Lucía Spangenberg6,7.   

Abstract

BACKGROUND: Lissencephaly (LIS) is a cortical malformation, characterized by smooth or nearly smooth cerebral surface and a shortage of gyral and sulcal development, which is caused by deficient neuronal migration during embryogenesis. Neuronal migration involves many gene products, among which is the product of the PAFAH1B1 gene, associated with this disease. LIS is a rare disease, characterized by low population frequency, and with non-specific clinical symptoms such as early epilepsy, developmental delay or cerebral palsy-like motor problems. Given that high-throughput sequencing techniques have been improving diagnosis, we have chosen this technique for addressing this patient. CASE
PRESENTATION: We present the case of a seven years old male patient with an undiagnosed rare disease, with non-specific clinical symptoms possibly compatible with lissencephaly. The patient was enrolled in a study that included the sequencing of his whole genome. Sequence data was analyzed following a bioinformatic pipeline. The variants obtained were annotated and then subjected to different filters for prioritization. Also mitochondrial genome was analyzed. A novel candidate frameshift insertion in known PAFAH1B1 gene was found, explaining the index case phenotype. The assessment through in silico tools reported that it causes nonsense mediated mechanisms and that it is damaging with high confidence scores. The insertion causes a change in the reading frame, and produces a premature stop codon, severely affecting the protein function and probably the silencing of one allele. The healthy mother did not carry the mutation, and the unaffected father was not available for analysis.
CONCLUSIONS: Through this work we found a novel de novo mutation in LIS1/PAFAH1B1 gene, as a likely cause of a rare disease in a young boy with non-specific clinical symptoms. The mutation found correlates with the phenotype studied since the loss of function in the gene product has already been described in this condition. Since there are no other variants in the PAFAH1B1 gene with low population frequency and due to family history, a de novo disease mechanism is proposed.
© 2022. The Author(s).

Entities:  

Keywords:  Case report; Lissencephaly; Novel mutation; PAFAH1B1; Rare disease; Whole-genome sequencing

Mesh:

Substances:

Year:  2022        PMID: 36100855      PMCID: PMC9472359          DOI: 10.1186/s12887-022-03595-6

Source DB:  PubMed          Journal:  BMC Pediatr        ISSN: 1471-2431            Impact factor:   2.567


Background

Lissencephaly (LIS) is a subtype of malformations of cortical development (MCD), which are a heterogenous group of disorders with diverse phenotypic and genotypic presentations. Patients with LIS may present different degrees of developmental delays, seizures, severe psychomotor impairment, muscle spasticity or hypotonia [1]. Lissencephaly is a disorder caused by a defect in neuronal migration, which occurs between 12 and 24 weeks of gestation and results in a lack of development of brain folds (gyri) and grooves (sulci) [2]. Neuronal migration is a complex process, which requires the coordination of many gene products. LIS1 and DCX were the first genes that were associated with LIS, discovered in 1993 and 1998, respectively [3, 4]. In the past years with the advent of new molecular genomics technologies, many additional genes were found. These LIS-related genes include ACTB, ACTG1, ARX, CDK5, CRADD, DYNC1H1, KIF2A, KIF5C, NDE1/NDEL1, TUBA1A, TUBA8, TUBB, TUBB2B, TUBB3, TUBG1, RELN and VLDLR. Many of these 19 LIS-associated genes are related to microtubule structural proteins (tubulin) or microtubule-associated proteins [5]. The PAFAH1B1 gene (Genbank accession number: NM_000430), located at chromosome 17p13.3, encodes the alpha subunit of the 1B isoform of the platelet-activation factor acetylhydrolase regulatory, a highly conserved protein of 410 amino acids, known as LIS1 or PAFAH1B1 [6]. It has two protein coding transcripts and several non-coding ones. LIS1/PAFAH1B1 forms the non-catalytic subunit of the G protein-like heterotrimeric cytosolic platelet-activating factor acetylhydrolase (PAF-AH) brain isoform Ib (PAFAH1B1) [7]. Along with two other subunits, PAFAH1B2 and PAFAH1B3, LIS1/PAFAH1B1 forms a trimeric complex which regulates the level of platelet activating factor (PAF) in the brain, by catalyzing the removal of the acetyl group at the SN-2 position of platelet-activating factor [8, 9]. The regulation of optimal concentrations of PAF in the brain may be critical for correct neuronal migration, essential for normal brain development and function. LIS1/PAFAH1B1 has also been shown to play a central role in the organization of the cytoskeleton, which in turn affects neuronal proliferation and migration [6]. Mutations in this gene have previously been associated with cortical brain malformation in children (Table 1).
Table 1

Mutations in LIS1/PAFAH1B1 gene associated with cortical brain malformation available in ClinVar [10]. All mutations are associated with lissencephaly phenotype but two that are marked with *(associated with Subcortical band heterotopia) and ** (associated with abnormal cortical gyration)

NameProtein changeMutation typeAccessionGRCh37LocationdbSNP ID
Likely Pathogenic
 c.1142A > G (p.His381Arg)H381RmissenseVCV0009315832,583,597rs2069361452
 c.967 T > A (p.Trp323Arg)W323RmissenseVCV0008121822,579,865rs2069271269
 c.900G > C (p.Glu300Asp)E300DmissenseVCV0004361412,577,582rs587784291
 c.121G > A (p.Glu41Lys)E41KmissenseVCV0001595032,569,313rs587784250
 c.503G > A (p.Cys168Tyr)C168YmissenseVCV0001595252,573,560rs200390886
 c.569-3delnon codingVCV0002118272,575,943rs797045863
 c.671 + 4A > Gnon codingVCV0001595362,576,055rs587784279
 c.671 + 5G > Anon codingVCV0001595372,576,056rs587784280
 c.751A > C (p.Ser251Arg)S251RmissenseVCV0001595452,577,433rs587784287
 c.900G > A (p.Glu300 =)missenseVCV0001595502,577,582rs587784291
 c.938C > T (p.Ser313Phe)S313FmissenseVCV0001595522,579,836rs587784293
 c.965 T > G (p.Met322Arg)M322RmissenseVCV0001595532,579,863rs587784294
 c.1193G > A (p.Gly398Asp)G398DmissenseVCV0001595002,585,056rs587784247
 NC_000017.11:g.(?_2638238)_(2638345_?)dellarge deletionVCV0004952792,541,532—2,541,639
 NC_000017.11:g.(?_2680139)_(2681852_?)dellarge deletionVCV0004952782,583,433—2,585,146
 c.899A > G (p.Glu300Gly)E300GmissenseVCV0004361402,577,581rs1555527149
 c.400-1G > Asplicing acceptorVCV0015260612,573,456
 c.661G > A (p.Val221Met)V221MmissenseVCV0009313482,576,041rs1262666760
 c.1009C > G (p.His337Asp)H337DmissenseVCV0001594882,583,464rs587784236
 c.1190C > T (p.Thr397Ile)T397ImissenseVCV0004292772,585,053rs1131691295
 c.722G > C (p.Arg241Pro)*R241PmissenseVCV0000080802,577,404rs121434488
Pathogenic
 c.441dup (p.Gly148fs)G148fsframe shiftVCV0002118252,573,495—2,573,496rs797045861
 c.162dup (p.Trp55fs)W55fsframe shiftVCV0000211812,569,346—2,569,347rs113994198
 c.770_772delinsTGACCCA (p.Thr257fs)T257fsframe shiftVCV0002118322,577,452—2,577,454rs797045868
 c.716dup (p.Met239fs)M239fsframe shiftVCV0001595422,577,397—2,577,398rs587784284
 c.1050del (p.Lys351fs)K351fsframe shiftVCV0000211762,583,500rs113994200
 c.703_704del (p.Glu235fs)E235fsframe shiftVCV0002118292,577,382—2,577,383rs797045865
 c.3G > A (p.Met1Ile)M1ImissenseVCV0001595202,541,585rs587784265
 c.33-3C > Tnon codingVCV0001595142,568,663rs587784260
 c.37C > T (p.Arg13Ter)R13*stop gainVCV0001595162,568,670rs587784262
 c.56 T > G (p.Leu19Arg)L19RmissenseVCV0001595292,568,689rs587784272
 c.71_72dup (p.Glu25fs)E25fsframe shiftVCV0002118302,568,702—2,568,703rs797045866
 c.72 T > G (p.Tyr24Ter)Y24*stop gainVCV0001595432,568,705rs587784285
 c.84 T > G (p.Tyr28Ter)Y28*stop gainVCV0001595472,568,717rs369259961
 c.136_137del (p.Lys46fs)K46fsframe shiftVCV0001595052,569,325—2,569,326rs587784252
 c.152del (p.Leu51fs)L51fsframe shiftVCV0001595062,569,341rs587784253
 c.190_192 + 5dupsplice donorVCV0002118202,569,381—2,569,382rs797045857
 c.192G > C (p.Lys64Asn)K64NmissenseVCV0001595112,569,384rs587784257
 c.192 + 1G > Tsplice donorVCV0001595102,569,385rs587784256
 c.192 + 1G > Asplice donorVCV0001595092,569,385rs587784256
 c.288_289dup (p.Arg97fs)R97fsframe shiftVCV0002118212,570,378—2,570,379rs797045858
 c.371 T > A (p.Val124Asp)V124DmissenseVCV0001595152,570,464rs587784261
 c.386A > T (p.Asp129Val)D129VmissenseVCV0001595172,570,479rs587784263
 c.399 + 1G > Asplice donorVCV0001595192,570,493rs587784264
 c.405G > A (p.Trp135Ter)W135*stop gainVCV0001595212,573,462rs587784266
 c.455_456del (p.Ser152fs)S152fsframe shiftVCV0001595232,573,510—2,573,511rs587784268
 c.460C > T (p.Gln154Ter)Q154*stop gainVCV0001595242,573,517rs587784269
 c.484G > A (p.Gly162Ser)G162SmissenseVCV0000080792,573,541rs121434487
 c.524_528del (p.Lys175fs)K175fsframe shiftVCV0001595262,573,579—2,573,583rs587784270
 c.537dup (p.Gln180fs)Q180fsframe shiftVCV0002118262,573,590—2,573,591rs587784271
 c.537del (p.Gln180fs)Q180fsframe shiftVCV0001595272,573,591rs587784271
 c.632C > G (p.Ser211Ter)S211*stop gainVCV0001595302,576,012rs587784273
 c.644_651del (p.Thr215fs)T215fsframe shiftVCV0001595312,576,018—2,576,025rs587784274
 c.647_648del (p.Ile216fs)I216fsframe shiftVCV0001595322,576,025—2,576,026rs587784275
 c.658del (p.Glu220fs)E220fsframe shiftVCV0001595342,576,036rs587784277
 c.657G > A (p.Trp219Ter)W219*stop gainVCV0001595332,576,037rs587784276
 c.667dup (p.Thr223fs)T223fsframe shiftVCV0002118282,576,044—2,576,045rs797045864
 c.664C > T (p.Gln222Ter)Q222*stop gainVCV0001595352,576,044rs587784278
 c.671G > A (p.Gly224Asp)G224DmissenseVCV0001595382,576,051rs587784281
 c.675C > G (p.Tyr225Ter)Y225*stop gainVCV0001595392,577,357rs587784282
 c.728_732dup (p.Asp245fs)D245fsframe shiftVCV0002118312,577,406—2,577,407rs797045867
 c.730C > T (p.Gln244Ter)Q244*stop gainVCV0001595442,577,412rs587784286
 c.773_774del (p.Val258fs)V258fsframe shiftVCV0002118332,577,453—2,577,454rs797045869
 c.829dup (p.His277fs)H277fsframe shiftVCV0002118342,577,510—2,577,511rs797045870
 c.841 T > C (p.Cys281Arg)C281RmissenseVCV0001595462,577,523rs587784288
 c.851G > A (p.Trp284Ter)W284*stop gainVCV0001595482,577,533rs587784289
 c.900 + 1G > Asplice donorVCV0001595492,577,583rs587784290
 c.933dup (p.Leu312fs)L312fsframe shiftVCV0002118362,579,830—2,579,831rs797045872
 c.1002 + 1G > Asplice donorVCV0000211752,579,901rs113994203
 c.1002 + 5G > Anon codingVCV0001594862,579,905rs587784235
 c.1003-30_1032delsplice acceptorVCV0002118172,583,426—2,583,485rs1555527743
 c.1009C > T (p.His337Tyr)H337YmissenseVCV0001594892,583,464rs587784236
 c.1018dup (p.Trp340fs)W340fsframe shiftVCV0002118182,583,472—2,583,473rs797045855
 c.1024_1031del (p.Arg342fs)R342fsframe shiftVCV0001594902,583,479—2,583,486rs587784237
 c.1050dup (p.Lys351fs)K351fsframe shiftVCV0000211772,583,499—2,583,500rs113994200
 c.1063del (p.Ser355fs)S355fsframe shiftVCV0001594912,583,518rs587784238
 c.1064G > A (p.Ser355Asn)S355NmissenseVCV0001594922,583,519rs587784239
 c.1100del (p.Tyr367fs)Y367fsframe shiftVCV0001594932,583,555rs587784240
 c.1135C > T (p.His379Tyr)H379YmissenseVCV0001594952,583,590rs587784242
 c.1159G > T (p.Asp387Tyr)D387YmissenseVCV0001594972,583,614rs587784244
 c.1165C > T (p.His389Tyr)H389YmissenseVCV0001594982,585,028rs587784245
 c.1196G > C (p.Ser399Thr)S399TmissenseVCV0001595012,585,059rs587784248
 c.1201G > C (p.Asp401His)D401HmissenseVCV0001595022,585,064rs587784249
 c.1233A > C (p.Ter411Cys)stop lostVCV0001595042,585,096rs587784251
 c.1111C > T (p.Arg371Ter)R371*stop gainVCV0001594942,583,566rs587784241
 c.568 + 1G > Asplice donorVCV0004361372,573,626rs1555526733
 c.162del (p.Lys54fs)K54fsframe shiftVCV0000211802,569,347rs113994198
 c.265C > T (p.Arg89Ter)R89*stop gainVCV0001595122,570,358rs587784258
 c.817C > T (p.Arg273Ter)R273*stop gainVCV0000080742,577,499rs121434483
 c.305dup (p.Tyr102Ter)Y102*stop gainVCV0001595132,570,397—2,570,398rs587784259
 c.347dup (p.His117fs)H117fsframe shiftVCV0002118232,570,436—2,570,437rs797045859
 c.368 T > A (p.Met123Lys)**M123KmissenseVCV0010771342,570,461
 c.523A > T (p.Lys175Ter)K175*stop gainVCV0002091802,573,580rs797045061
 c.910del (p.Ser304fs)S304fsframe shiftVCV0001595512,579,802rs587784292
 c.911del (p.Ser304fs)S304fsframe shiftVCV0002118352,579,809rs797045871
 c.852G > A (p.Trp284Ter)W284*stop gainVCV0005610722,577,534rs1567559851
 c.514dup (p.Met172fs)M172fsframe shiftVCV0004361362,573,570—2,573,571rs1555526718
 c.430C > T (p.Arg144Ter)R144*stop gainVCV0001595222,573,487rs587784267
 c.1159 + 1G > Asplice donorVCV0003791622,583,615rs1057520515
 c.1159 + 2 T > Asplice donorVCV0001594962,583,616rs587784243
 c.569-10 T > Cnon codingVCV0000211822,575,939rs113994202
 c.681dupGL228Glufsframe shiftthis paper
Mutations in LIS1/PAFAH1B1 gene associated with cortical brain malformation available in ClinVar [10]. All mutations are associated with lissencephaly phenotype but two that are marked with *(associated with Subcortical band heterotopia) and ** (associated with abnormal cortical gyration) Here, we comment on the case of a seven years old boy with an undiagnosed rare disease, with non-specific symptoms that could be compatible with LIS, but with an unclear presentation. Whole genome sequencing (WGS) of the patient was performed in the context of a genomics project (urugenomes.org) and sequence data was analyzed following a bioinformatics pipeline which concluded with a set of annotated and prioritized variants. A novel candidate frameshift variant was found that fits with the boy’s phenotype. To support the pathogenicity of the variant we used computational prediction tools and made segregation analysis with Sanger sequencing. To the best of our knowledge this is the first time this variant is reported [11] and it is the most likely cause of the patient’s disease.

Case presentation

The index case is a seven years old boy with perinatal clinical records of poorly controlled pregnancy, homelessness and multiple drugs abuse through all gestation. Both parents are healthy and non-consanguineous. Early term delivery, low birthweight with microcephaly at birth with a head circumference of 32 cm (Z score -3). The patient develops a spastic bilateral cerebral palsy, Gross Motor Function Classification System (GMFSC) IV, Bimanual fine motor function (BFMF) IVa, Communication Function Classification System (CFCS) IV. Associated with a profound intellectual disability, visual and auditory sensory deficit, pharmacoresistant epilepsy with generalized tonic clonic seizures, and congenital microcephaly with a head circumference growth always under -3 standard deviations. No dysmorphic signs were detected. Cerebral magnetic resonance imaging (MRI) shows a diffuse lissencephaly-pachygyria spectrum with main affectation at posterior brain areas (Fig. 1).
Fig. 1

MRI results. A Volumetric T1 brain MRI axial and B Sagittal planes show a diffuse lissencephaly-pachygyria spectrum predominantly in the posterior areas methylation study for Angelman syndrome was normal and the sequencing of ARX and MECP2 showed no pathogenic mutations

MRI results. A Volumetric T1 brain MRI axial and B Sagittal planes show a diffuse lissencephaly-pachygyria spectrum predominantly in the posterior areas methylation study for Angelman syndrome was normal and the sequencing of ARX and MECP2 showed no pathogenic mutations

Genetic and evolutionary analysis

Whole genome sequencing (WGS) of the patient was performed and sequence data was analyzed following a bioinformatic pipeline which included analysis of the quality of reads [12], mapping onto human reference genome (hg19) [13], mark of duplicates, sorting and variant calling [14]. The variants obtained were annotated [15] and then subjected to different sets of filters to detect potentially causative mutations (see Supplementary Material). After these filters were applied, we obtained 40 homozygous or hemizygous variants with population frequency less than 1% located at splicing sites or coding regions, 458 heterozygous variants with population frequency less than 1% and 439 heterozygous variants with population frequency less than 0.5% and located at splicing sites or coding regions. Among these prioritized variants we found a potential causative mutation in heterozygous state in the LIS1/PAFAH1B1 gene. This gene was previously associated with the phenotype (LIS), especially with an autosomal dominant mechanism of inheritance. The potential causative mutation found is a frameshift insertion of a single nucleotide in exon 8 (PAFAH1B1:NM_000430:exon8:c.681dupG:p.(Lys228Glufs*28)), that lies between the first 23% to 55% of the protein depending on the transcript, according to the SIFT Indel tool [16]. The frameshift indel was reported as damaging with a confidence score of 0.858, and causing a nonsense mediated decay (NMD) response. It generates a premature stop codon 27 amino acids later, causing the loss of 156 amino acids. If the mutated gene evaded NMD and led to a final product, this would be a 254 amino acids protein instead of the wild type 410 residues. A crystal structure has been described for LIS1 complexed to the brain cytosolic PAF-AH [17]. The complex shows that LIS1 folds into a beta propeller and interacts as a homodimer with a PAF-AH homodimer. From 14 reported surface interacting residues with PAF-AH, 8 are missing from our patient’s hypothetical protein. We predict that the mutated LIS1 could have self-aggregation tendencies, as the 27 new residues composing the shorter C-terminal region, not only would not allow the correct folding into a complete beta-propeller, but in addition would be highly disordered. As a qualitative indicator for this, the homology model in this C-terminal region has very low quality, in particular for the ‘HRTQRMGTY’ amino acid stretch, according to QMEANDiscO scoring function [18]. Even without aggregation and assuming the protein could fold into a ‘half propeller’, this protein would be unable to productively interact with PAF-AH as well as its additional molecular partners, notably dynein and a number of dynein-associated proteins. Indeed, LIS1 has been described as a molecular hub at a crossroad of several pathways, coupling PAF signaling to dynein regulation [17]. We expect all these functions to be hampered or inexistent in the protein product coded by this allelet. The unaffected mother was sequenced at the proposed variant position and no mutation was detected. This is considered to support the hypothesis of a de novo mutation in the patient. Unfortunately the father of the patient (also unaffected) was not available for analysis. Figure 2 A shows an IGV view of the candidate position. 37 reads are covering that location with a good quality. Additionally, the variant was confirmed with Sanger Sequencing in the patient (Fig. 2B, top) and was not seen in the mother (Fig. 2B, bottom)
Fig. 2

Variant impact at genome and protein level. A IGV view of the reads mapping onto the gene PAFAH1B1. The gene’s structure is shown on top and the exon, where the mutation is located is marked with an asterisk. The reads are shown in gray and the Insertion is marked in violet. The inserted G is shown on top of the reference genome. The originated premature stop codon is also marked. B Sanger sequencing of the variant in mother (top) and patient (bottom). Mother presents no variant, while patient variant was confirmed. C Top view of the truncated LIS1 beta propeller in orange. The C-terminal region of 27 residues introduced between the frameshift and the stop codon is painted in red. For reference, the wild-type crystal structure of LIS1 (PDB access code 1VYH) is shown superimposed as a transparent grey cartoon. Also, eight crucial interacting residues  are indicated in atom sticks, completely absent from the hypothetical truncated LIS1

Variant impact at genome and protein level. A IGV view of the reads mapping onto the gene PAFAH1B1. The gene’s structure is shown on top and the exon, where the mutation is located is marked with an asterisk. The reads are shown in gray and the Insertion is marked in violet. The inserted G is shown on top of the reference genome. The originated premature stop codon is also marked. B Sanger sequencing of the variant in mother (top) and patient (bottom). Mother presents no variant, while patient variant was confirmed. C Top view of the truncated LIS1 beta propeller in orange. The C-terminal region of 27 residues introduced between the frameshift and the stop codon is painted in red. For reference, the wild-type crystal structure of LIS1 (PDB access code 1VYH) is shown superimposed as a transparent grey cartoon. Also, eight crucial interacting residues  are indicated in atom sticks, completely absent from the hypothetical truncated LIS1

Discussion and conclusion

We found a novel probably causative frameshift variant in a patient with a previously undiagnosed rare disease using WGS. Previous genetic tests (sequencing of MECP2 and ARX genes, and methylation analysis for Angelman syndrome) were performed with inconclusive results. This is expected since Lissencephaly and epileptic encephalopathy are highly heterogeneous genetic disorders in their etiology: ie. different genes are associated with several presentations of this pathology. For example, RELN gene is affected in the Norman-Roberts syndrome (LIS2) [19], heterozygous mutations in TUBA1A are responsible for the LIS3 syndrome [20], homozygous mutations in the NDE1 gene are associated to LIS4 [21], among many others (LAMB1 to LIS5 [22], KATNB1 to LIS6 [23], CDK5 to LIS7 [24], TMTC to LIS8 [25], MACF1 LIS9 [26], CEP85L LIS10 [27]). Additionally X-linked forms of Lissencephaly are caused by DCX and ARX genes [28]. Hence, usually WGS or WES are accurate strategies for assessing patients with epileptic encephalopathy. However, in this case if we had had the MRI results (fairly consistent with LIS) before we had done the NGS sequencing, we might have end up doing a targeted sequencing approach, such as the PAFAH1B1 gene or at least a subset of genes or WES, instead of doing the complete genome. This being a matter of costs and resources and not crucial for the patient’s diagnosis. The variant we detected was an insertion of one nucleotide (G) in the coding sequence of LIS1 gene, causing a change in the reading frame. The localization of the variant corresponds to the first 23% to 55% of the protein (depending on the transcript) and as a consequence a premature stop codon is produced causing the loss of the last 156 amino acids of the protein. Therefore, a severe affectation of the protein function is expected and probably a silencing of this allele either by encoding a truncated protein or by the mechanism of degradation of messenger RNA mediated by terminator mutations (NMD). This variant has not been previously described and does not appear in the population frequency databases. It corresponds to the phenotype of the patient and the loss of function in the gene product is a mechanism already described in this condition (truncating mutations were described in other patients and being the gene involved in the microdeletion of Miller-Dieker lissencephaly syndrome). Since there are no other variants in the LIS1/PAFAH1B1 gene with less than 1% population frequency and due to family history, we proposed a de novo mechanism for this case. This was (partially) confirmed by Sanger sequencing of the mother who doesn’t have the mutation. Father was unavailable for analysis, so this aspect remains unknown. Nevertheless, we consider that there is sufficient evidence that supports the pathogenic classification of the novel variant. According to ACMG (American College of Medical Genetics and Genomics) variant interpretation guidelines [29] the frameshift variant found corresponds to the PVS1 (pathogenicity very strong) rule. It is a null variant (frameshift) in a gene where loss of function (LOF) is a known mechanism of disease (in ExAC database PAFAH1B1 gene has a maximal probability of being LOF intolerant, pLI = 1 [30]). The frameshift mutation is also classified as a PM2 (moderate evidence of pathogenicity) since it was absent in population databases (1000 Genomes Project, GnomAD, etc.). We also consider applying rule PP4 (Patient’s phenotype is highly specific for a disease with a single genetic etiology), since the MRI findings are very specific for PAFAH1B1-related LIS. According to ACMG rules, the variant is classified as pathogenic, as it belongs to one very strong (PVS1), one moderate (PM2) and one supporting category (PP4). We could also consider applying PP3 (supporting evidence of pathogenicity) since the pathogenic computational verdict is based on one pathogenic prediction from SIFT Indel Tool, one pathogenic prediction from the conservation score GERP [31] and no benign predictions. However, some studies avoid [32] applying PP3 in LoF variants when PVS1 is valid. Furthermore there are other disruptive (frameshift or stop codon) variants in the same gene region reported as pathogenic [33], supporting the importance of the region for proper gene product function. Through this work we were able to find a molecular diagnosis of a rare disease in a seven years old boy with severe and heterogeneous neurological symptoms. We found a de novo novel frameshift mutation in the LIS1/PAFAH1B1 gene that most likely causes a silencing of one allele. This finding shows the benefit of the use of NGS as a diagnosis tool of rare diseases. Additional file 1.
  29 in total

1.  SIFT: Predicting amino acid changes that affect protein function.

Authors:  Pauline C Ng; Steven Henikoff
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

2.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.

Authors:  Aaron McKenna; Matthew Hanna; Eric Banks; Andrey Sivachenko; Kristian Cibulskis; Andrew Kernytsky; Kiran Garimella; David Altshuler; Stacey Gabriel; Mark Daly; Mark A DePristo
Journal:  Genome Res       Date:  2010-07-19       Impact factor: 9.043

3.  Lissencephaly: Expanded imaging and clinical classification.

Authors:  Nataliya Di Donato; Sara Chiari; Ghayda M Mirzaa; Kimberly Aldinger; Elena Parrini; Carissa Olds; A James Barkovich; Renzo Guerrini; William B Dobyns
Journal:  Am J Med Genet A       Date:  2017-04-25       Impact factor: 2.802

4.  Doublecortin, a brain-specific gene mutated in human X-linked lissencephaly and double cortex syndrome, encodes a putative signaling protein.

Authors:  J G Gleeson; K M Allen; J W Fox; E D Lamperti; S Berkovic; I Scheffer; E C Cooper; W B Dobyns; S R Minnerath; M E Ross; C A Walsh
Journal:  Cell       Date:  1998-01-09       Impact factor: 41.582

5.  Developmental aspects of lissencephaly and the lissencephaly syndromes.

Authors:  W B Dobyns
Journal:  Birth Defects Orig Artic Ser       Date:  1987

6.  Autosomal recessive lissencephaly with cerebellar hypoplasia is associated with human RELN mutations.

Authors:  S E Hong; Y Y Shugart; D T Huang; S A Shahwan; P E Grant; J O Hourihane; N D Martin; C A Walsh
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

7.  Mutations in KATNB1 cause complex cerebral malformations by disrupting asymmetrically dividing neural progenitors.

Authors:  Ketu Mishra-Gorur; Ahmet Okay Çağlayan; Ashleigh E Schaffer; Chiswili Chabu; Octavian Henegariu; Fernando Vonhoff; Gözde Tuğce Akgümüş; Sayoko Nishimura; Wenqi Han; Shu Tu; Burçin Baran; Hakan Gümüş; Cengiz Dilber; Maha S Zaki; Heba A A Hossni; Jean-Baptiste Rivière; Hülya Kayserili; Emily G Spencer; Rasim Ö Rosti; Jana Schroth; Hüseyin Per; Caner Çağlar; Çağri Çağlar; Duygu Dölen; Jacob F Baranoski; Sefer Kumandaş; Frank J Minja; E Zeynep Erson-Omay; Shrikant M Mane; Richard P Lifton; Tian Xu; Haig Keshishian; William B Dobyns; Neil C Chi; Nenad Šestan; Angeliki Louvi; Kaya Bilgüvar; Katsuhito Yasuno; Joseph G Gleeson; Murat Günel
Journal:  Neuron       Date:  2014-12-17       Impact factor: 17.173

8.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

9.  Analysis of protein-coding genetic variation in 60,706 humans.

Authors:  Monkol Lek; Konrad J Karczewski; Eric V Minikel; Kaitlin E Samocha; Eric Banks; Timothy Fennell; Anne H O'Donnell-Luria; James S Ware; Andrew J Hill; Beryl B Cummings; Taru Tukiainen; Daniel P Birnbaum; Jack A Kosmicki; Laramie E Duncan; Karol Estrada; Fengmei Zhao; James Zou; Emma Pierce-Hoffman; Joanne Berghout; David N Cooper; Nicole Deflaux; Mark DePristo; Ron Do; Jason Flannick; Menachem Fromer; Laura Gauthier; Jackie Goldstein; Namrata Gupta; Daniel Howrigan; Adam Kiezun; Mitja I Kurki; Ami Levy Moonshine; Pradeep Natarajan; Lorena Orozco; Gina M Peloso; Ryan Poplin; Manuel A Rivas; Valentin Ruano-Rubio; Samuel A Rose; Douglas M Ruderfer; Khalid Shakir; Peter D Stenson; Christine Stevens; Brett P Thomas; Grace Tiao; Maria T Tusie-Luna; Ben Weisburd; Hong-Hee Won; Dongmei Yu; David M Altshuler; Diego Ardissino; Michael Boehnke; John Danesh; Stacey Donnelly; Roberto Elosua; Jose C Florez; Stacey B Gabriel; Gad Getz; Stephen J Glatt; Christina M Hultman; Sekar Kathiresan; Markku Laakso; Steven McCarroll; Mark I McCarthy; Dermot McGovern; Ruth McPherson; Benjamin M Neale; Aarno Palotie; Shaun M Purcell; Danish Saleheen; Jeremiah M Scharf; Pamela Sklar; Patrick F Sullivan; Jaakko Tuomilehto; Ming T Tsuang; Hugh C Watkins; James G Wilson; Mark J Daly; Daniel G MacArthur
Journal:  Nature       Date:  2016-08-18       Impact factor: 49.962

10.  Pathogenic Variants in CEP85L Cause Sporadic and Familial Posterior Predominant Lissencephaly.

Authors:  Meng-Han Tsai; Alison M Muir; Won-Jing Wang; Yi-Ning Kang; Kun-Chuan Yang; Nian-Hsin Chao; Mei-Feng Wu; Ying-Chao Chang; Brenda E Porter; Laura A Jansen; Guillaume Sebire; Nicolas Deconinck; Wen-Lang Fan; Shih-Chi Su; Wen-Hung Chung; Edith P Almanza Fuerte; Michele G Mehaffey; Ching-Ching Ng; Chung-Kin Chan; Kheng-Seang Lim; Richard J Leventer; Paul J Lockhart; Kate Riney; John A Damiano; Michael S Hildebrand; Ghayda M Mirzaa; William B Dobyns; Samuel F Berkovic; Ingrid E Scheffer; Jin-Wu Tsai; Heather C Mefford
Journal:  Neuron       Date:  2020-02-24       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.